HIV/AIDS Treatment Trends and Progress: Where Do We Stand Today?
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
Address: 7 Malibongwe Drive
Fontainebleau, Randburg
Gauteng,South Africa
Tel: + 27 11 792-7120
Web: http://www.omnimed.co.za/
OmniMed (Pty) Ltd was founded in 1960 and its main activity was the manufacture of sterile intravenous solutions under license to a leading German manufacturer. The name of the Company at the time was Remedia Medical.
In time, the Company diversified into other forms of pharmaceutical manufacture but as it evolved, it embarked upon new ventures focusing on the hospital and specialist doctor market. It acquired new licenses offering a broad spectrum of hospital consumables and equipment.
Today OmniMed owes its diversity to its ability to adapt to changing markets. Due to its long-standing presence in the market, leading product portfolio and strong customer service, OmniMed is well known in both the Private and Public Health Care sectors.
Life-saving technologies, as well as products that improve the quality of life have always been the trademark of OmniMed.
OmniMed also provides administration and distribution services to BioMerieux SA a leading French Diagnostic company on a fee for service basis.
The manufacturing operation is located in Johannesburg and OmniMed has a fully owned well-established subsidiary in Namibia.
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
Dr Benji Pretorius, the founder of Erada Technology Alliance and a malaria survivor himself, shares his insights into why the development of a truly effective malaria vaccine will only succeed…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Nevena Miletic of Roche and the IFPMA’s Africa Regulatory Network and Ian Hudson from the Bill and Melinda Gates…
The third and final piece in Lenias Hwenda of Medicines for Africa’s series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential…
The second in a three-part series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come (read part one…
In the first of a series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come, Lenias Hwenda of…
During the COVID-19 pandemic discussions around increasing access to medicines for low and middle-income countries (LMICs) were often centred on compulsory licensing. As a result, pharma companies were up in…
As part of a special focus on drug development and clinical research in Africa in February 2023’s DIA Global Forum magazine, Lisa Ursella Collins of Innomas Clinical Research, Leslie Sam…
Roughly half of Africa’s 1.1 billion people lack regular access to even the most essential medicines and most of Sub-Saharan Africa depends on imports which make up as much as…
Speaking exclusively to PharmaBoardroom, Medicines for Africa’s Lenias Hwenda gives a comprehensive overview of the African Medicines Agency, why such a regulatory body was needed, how it differs from the…
Lenias Hwenda of Medicines for Africa examines the true impact of access to medicine initiatives in Africa, noting that many of the measures takes are often cosmetic and leave a…
Some of the top pharma news coming out of South Africa including Afrigen’s partnership with US National Institutes of Health (NIH), BioNTech’s efforts to bring an mRNA start-to-finish vaccine manufacturing network…
See our Cookie Privacy Policy Here
